

Isolation and Identification of a Vardenafil Analogue in a Dietary Supplement

KUO-CHIH LAI¹, YI-CHU LIU¹, MU-CHANG TSENG¹, YUN-LIAN LIN² AND JER-HUEI LIN^{1*}

¹ Bureau of Food and Drug Analysis, Department of Health, Executive Yuan, 161-2, Kunyang St., Nangang, Taipei 115, Taiwan, R.O.C.

² Natiearch Institute of Chinese Medicine, 155-1, Sec. 2, Linong St., Beitou, Taipei 112, Taiwan, R.O.C.

(Received: August 31, 2006; Accepted: March 13, 2007)

ABSTRACT

A vardenafil analogue was found to be added illegally into a dietary supplement marketed for erectile dysfunction. Its structure was determined as 2-(2-ethoxyphenyl)-5-methyl-7-propyl-imidazo[5,1-f][1,2,4]triazin-4(3H)-one. The sample was extracted with ethanol and isolated by column chromatography. The structure was identified with a series of 1-D and 2-D NMR techniques and LC/MS/MS. Having compared with structure of vardenafil, the data showed that the ethylpiperazinyl and sulfonyl of vardenafil were removed from the phenyl group. Since its structure was similar to that of vardenafil, side effects of vardenafil might associate with this analogue. This vardenafil analogue has been included in the inspection list of illegal adulterants in Taiwan.

Key words: vardenafil analogue, LC/MS/MS, NMR

INTRODUCTION

Sildenafil and vardenafil, two PDE (phosphodiesterase) inhibitors, are used popularly as orally effective drugs in the treatment of male erectile dysfunction^(1,2), despite their association with several serious side effects⁽³⁾. A substantial identification system for sildenafil in health foods was reported using three different analytical methods, i.e. TLC, HPLC/MS and HPLC/PDA in Japan⁽⁴⁾. Four analogues, homosildenafil, acetildenafil, hydroxyhomosildenafil and piperidenafil were found from many functional foods marketed for penis erectile dysfunction in Korea⁽⁵⁾, Netherlands⁽⁶⁾ and USA⁽⁷⁾.

In our laboratory we have found adulterants such as sildenafil⁽⁸⁾, homosildenafil, acetildenafil⁽⁹⁾, hydroxyhomosildenafil⁽¹⁰⁾, tadalafil, vardenafil and piperidenafil in many dietary supplements (Figure 1). Another unknown compound A related to vardenafil was found in a dietary supplement marketed for enhancing male sex ability. Although its molecular weight and UV spectra were different from those of sildenafil, vardenafil and the above sildenafil analogues, the data of NMR indicated a vardenafil analogue was inferred.

MATERIALS AND METHODS

I. Equipments

The melting point was determined on a Fisher-Johns melting point apparatus. The LC/MS/MS was performed

using a Waters 2690 Alliance LC module, equipped with 996 photodiode array detector and Micromass Quattro Ultima tandem mass. The NMR spectra were recorded on a Bruker AMX-400 spectrometer (400 MHz for ¹H, 100 MHz for ¹³C) with dimethylsulfoxide-*d*₆ as solvent. All chemicals were of analytical grades.

II. Extraction and Isolation

Test samples were obtained from local markets and




Figure 1. Structure of sildenafil, vardenafil, tadalafil, vardenafil analogue and sildenafil analogues.

* Author for correspondence. Tel: +886-2-26531239; Fax: +886-2-26531244; E-mail: linjerhuei@nlfd.gov.tw

consumer service centers of the local health bureaus. Six capsules of sample (3.1 g) were extracted with ethanol, and the leftover was removed by filtration. The filtrate was dried under reduced pressure using a rotary evaporator at 40°C. The residue was subjected to a silica gel column chromatography using *n*-hexane with increasing amount of ethyl acetate as solvent. The target fractions were collected and recrystallized with methanol to yield the white crystal compound A (47.0 mg).

III. NMR Correlation Data of Compound A

The purified compound A was identified with a series of 1-D and 2-D NMR spectroscopic techniques, including ¹H, ¹³C, DEPT, COSY, HMQC and HMBC. The data are shown in Table 1.

IV. Analysis Condition of LC/MS/MS

HPLC of LC/MS/MS was carried out on a column of Cosmosil 5C₁₈-AR (4.6 × 150 mm, 5 μm) with methanol/0.25% formic acid (70:30) as mobile phase. The flow

rate was 0.3 mL/min, the injection volume was 10 μL, and the running time was 40 min. The eluate was monitored by a photo-diode array detector and scan range was 200~350 nm.

The analytical condition of tandem mass was as follows: positive ion electrospray (ES⁺) modes, daughter ion: 313.2, capillary voltage: 3.0 kV, cone voltage: 60 V, collision energy: 20 eV, source temperature: 120°C, and desolvation temperature: 300°C.

RESULT AND DISCUSSION

A silica gel column chromatography using *n*-hexane containing increasing amounts of ethyl acetate as solvent was applied to the separation and purification of compound A from one dietary supplement which claimed to enhance male sex ability. The isolated compound A was obtained as white crystal from methanol. The melting point was between 144 and 145°C.

Table 1 shows the ¹H-NMR, ¹³C-NMR, DEPT, ¹H-¹H COSY and HMBC spectral data of compound A.




Figure 2. ¹H spectrum of vardenafil analogue A.

Table 1. NMR correlation of vardenafil analogue A

No.	¹³ C (δ _C)	¹ H (δ _H)	DEPT	COSY	HMBC
2	147.5	-	0	-	H-6'
3	-	11.51 (1H, s)	-	-	-
4	155.1	-	0	-	-
4a	113.6	-	0	-	H-11
5	137.5	-	0	-	H-11
7	144.3	-	0	-	H-8/H-9
8	27.1	2.81 (2H, t, J = 7.6 Hz)	2	H-9	H-9/H-10
9	20.3	1.71 (2H, m)	2	H-8/H-10	H-8/H-10
10	13.7	0.91 (3H, t, J = 7.4 Hz)	3	H-9	H-8/H-9
11	14.2	2.49 (3H, s)	3	-	-
1'	120.1	-	0	-	H-6'/H-5'/H-3'
2'	156.8	-	0	-	H-6'/H-4'/H-3'/H-7'
3'	112.7	7.14 (1H, d, J = 8.4 Hz)	1	H-4'	H-5'/H-4'
4'	132.4	7.50 (1H, dd, J = 7.6, 8.4 Hz)	1	H-3'/H-5'	H-6'/H-5'/H-3'
5'	120.3	7.04 (1H, dd, J = 7.2, 6.8 Hz)	1	H-6'/H-4'	H-6'/H-4'/H-3'
6'	130.3	7.52 (1H, d, J = 7.6 Hz)	1	H-5'	H-5'/H-4'
7'	64.0	4.09 (2H, q, J = 7.0 Hz)	2	H-8'	H-8'
8'	14.5	1.30 (3H, t, J = 7.0 Hz)	3	H-7'	H-7'

δ¹³C in DMSO-d₆, J in Hz, 100 MHz for ¹³C, 400 MHz for ¹H
DEPT is the number of attached protons.




Figure 3. DEPT spectrum of vardenafil analogue A.

Angle




Figure 4. ^1H - ^1H COSY spectrum of vardenafil analogue A.




Figure 5. Partial ^1H - ^1H COSY spectrum of vardenafil analogue A.




Figure 6. HMQC spectrum of vardenafil analogue A.




Figure 7. HMBC spectrum of vardenafil analogue A.

The spectra were similar to that of vardenafil, except the ethylpiperazinyl and sulfonyl group were removed from phenyl moiety, was named as vardenafil analogue A. The $^1\text{H-NMR}$, DEPT, $^1\text{H-}^1\text{H COSY}$, HMQC and HMBC spectra of vardenafil analogue A are shown in Figures 2, 3, 4, 5, 6 and 7, respectively. The spectroscopic numbering used is given in Figure 8. All signals were assigned unequivocally according to the various NMR spectroscopic data.

The $^1\text{H-NMR}$ (Figure 2) spectrum showed characteristics of an amide at δ_{H} 11.51 (1H, s), four aromatic protons at δ_{H} 7.52 (1H, d, $J = 7.6$ Hz), 7.04 (1H, d, d, $J = 6.8, 7.2$ Hz), 7.50 (1H, d, d, $J = 7.6, 8.4$ Hz) and 7.14 (1H, d, $J = 8.4$ Hz), respectively. Two triplet peaks at δ_{H} 0.91 and δ_{H} 1.30 were assigned as the methyl group for $\text{H}_3\text{-10}$ and $\text{H}_3\text{-8}'$. One singlet peak at δ_{H} 2.49 was assigned as the methyl group for $\text{H}_3\text{-11}$. A methine signal of phenyl at δ_{H} 7.04 in this vardenafil analogue A was significantly different from vardenafil, which lacked this signal. Three




Figure 8. Structure of vardenafil analogue A.

peaks at δ_{H} 2.81, δ_{H} 1.71 and δ_{H} 4.09 were assigned as the methylene for $\text{H}_2\text{-8}$, $\text{H}_2\text{-9}$ and $\text{H}_2\text{-7}'$, respectively.

The $^{13}\text{C-NMR}$ and DEPT (Figure 3) spectra indicated three primary carbons, three secondary carbons, four tertiary carbons and seven quaternary carbons. One carbon peak at δ_{C} 155.1 belonged to lactam. Three methylene signals were shown at δ_{C} 27.1, δ_{C} 20.3 and δ_{C} 64.0 for C-8, C-9 and C-7'. Four methine peaks at δ_{C} 130.3, δ_{C} 120.3, δ_{C} 132.4 and δ_{C} 112.7 were assigned as the aromatic carbon for C-6', C-5', C-4' and C-3', respectively.

In the $^1\text{H-}^1\text{H COSY}$ (Figure 4) and Partial $^1\text{H-}^1\text{H}$




Figure 9. UV spectra of vardenafil and vardenafil analogue A.




Figure 10. The fragmentation of vardenafil and vardenafil analogue A.

COSY (Figure 5) spectra, the correlation of H-6'/H-5', H-5'/H-6', H-4', H-4'/H-5', H-3' and H-3'/H-4' exhibited the ethylpiperazinyl and sulfonyl group of vardenafil were removed from phenyl moiety.

In the HMQC (Figure 6) and HMBC (Figure 7) spectra, the correlation of H-7'/C-2' exhibited the attachment of the ethoxy group (δ_H 4.09, 1.30) to phenolic carbon (δ_C 156.8). The correlation of H-8 and H-9/C-7 showed the linkage of the propyl group (δ_H 2.81, 1.71, 0.91) to pyrazolic carbon (δ_C 144.3). The correlation of H-11/C-4a exhibited the attachment of a methyl group (δ_H 2.49) to the pyrimidine ring (δ_C 113.6). The correlation

between H-6' (δ_H 7.52) and C-2 (δ_C 147.5) suggested that the triazin ring linked to the benzene ring.

The UV spectrum of vardenafil analogue **A** was shown as λ_{max} at 248.4, 220.4 nm (Figure 9). Both the molecular weight and absorption of UV spectrum were different from those of vardenafil.

The [M+H] of vardenafil analogue **A** founded at m/z 313.2, corresponding to the molecular formula $C_{17}H_{20}O_2N_4$, 176 a.m.u. less than vardenafil ([M+H]: m/z 489.0) referred to ethylpiperazinyl and sulfonyl group. The fragmentation of vardenafil analogue **A** is shown in Figure 10. Possible fragmentation pathways of vardenafil analogue **A** is shown in Figure 10.




Figure 11. The possible fragmentation pathways of vardenafil analogue **A** at the LC/MS/MS.

Journal of Food and Drug Analysis, Vol. 15, No. 3, 2007

fil analogue **A** at the LC/MS/MS electrospray positive (ES⁺) are shown in Figure 11.

Based on the mass and NMR spectroscopic data, the structure of compound **A** was an analogue of vardenafil and was determined as 2-(2-ethoxyphenyl)-5-methyl-7-propyl-imidazo[5,1-*f*][1,2,4]triazin-4(3*H*)-one.

REFERENCES

1. Terrett, N. K., Bell, A. K., Brown, D. and Ellis, P. 1996. Sildenafil (Viagra) a potent and selective inhibitor of type-5 cyclic GMP phosphodiesterase with utility for the treatment of male erectile dysfunction. *Bioorg. Med. Chem. Lett.* 6: 1819-1824.
2. Boolell, M., Allen, M. J., Ballard, S. A., Gepi-Attee, S., Muirhead, G. J., Naylor, A. M., Osterloh, I. H. and Gingell, C. 1996. Sildenafil: an orally active type-5 cyclic GMP specific phosphodiesterase inhibitor for treatment of penile erectile dysfunction. *Int. J. Impotence Res.* 8: 47-52.
3. Beavo, J. A. 1995. Cyclic nucleotide phosphodiesterases functional implication of multiple isoforms. *Physiol. Rev.* 75: 725-748.
4. Takako, M., Sutemi, S., Kiyoko, K., Fusako, I., Jyunichi, N., Hisashi, K. and Ichiro, Y. 2001. Identification system for sildenafil in health foods. *Yakugaku Zasshi* 121: 765-769.
5. Shin, M. H., Hong, M. K., Kim, W. S., Lee, Y. J. and Jeoung, Y. C. 2003. Identification of a new analogue of sildenafil added illegally to a functional food marketed for penile erectile dysfunction. *Food Addit. Contam.* 20: 793-796.
6. Blok-Tip, L., Zomer, B., Bakker, F., Hartog, K. D., Hamzink, M., ten Hove, J., Vredenburg, M. and de Kaste, D. 2004. Structure elucidation of sildenafil analogues in herbal products. *Food Addit. Contam.* 21: 737-748.
7. Reepmeyer, J. C. and Woodruff, J. T. 2006. Use of liquid chromatography-mass spectrometry and a hydrolytic technique for the detection and structure elucidation of a novel synthetic vardenafil designer drug added illegally to a "natural" herbal dietary supplement. *J. Chromatogr. A* 1125: 67-75.
8. Tseng, M. C. and Lin, J. H. 2002. Determination of sildenafil citrate adulterated in a dietary supplement capsule by LC/MS/MS. *J. Food Drug Anal.* 10: 112-119.
9. Lai, K. C., Liu, Y. C., Tseng, M. C. and Lin, J. H. 2006. Isolation and identification of a sildenafil analogue illegally added in dietary supplements. *J. Food Drug Anal.* 14: 19-23.
10. Lin, M. C., Liu, Y. C. and Lin, J. H. 2006. Identification of a sildenafil analogue adulterated in two herbal food supplements. *J. Food Drug Anal.* 14: 260-264.